Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
February 5, 2020
Presentation
Key Opinion Leader Symposium: CG-806 for AML
Key Opinion Leader Symposium: CG-806 for AML:
View Presentation
December 9, 2019
Poster
2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas
2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas:
View Poster
December 8, 2019
Poster
2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells:
View Poster
December 7, 2019
Presentation
Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253
Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253:
View Presentation
October 24, 2019
Poster
2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML
2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML:
View Poster
June 14, 2019
Poster
2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR
2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR:
View Poster
May 16, 2019
Poster
24th Congress of The European Hematology Association 2019 - CG-806, Preclinical in Vivo Efficacy and Safety Profile as a Pan-FLT3/Pan-BTK Inhibitor
24th Congress of The European Hematology Association 2019 - CG-806, Preclinical in Vivo Efficacy and Safety Profile as a Pan-FLT3/Pan-BTK Inhibitor:
View Poster
April 1, 2019
Poster
2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients
2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients:
View Poster
April 1, 2019
Poster
2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells
2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells:
View Poster
Previous
1
2
3
4
5
6
7
8
Next